secwatch.observer — SEC 8-K summary
======================================

Issuer:     Third Harmonic Bio, Inc. (—)
CIK:        0001923840
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-001929
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

THRD appoints new CFO, provides THB335 update; IND filing on track for H1 2024
------------------------------------------------------------------------------

- Christopher M. Murphy appointed CFO and Business Officer effective Jan 4, 2024; base salary $495K, annual bonus up to 40%, option for 410,000 shares.
- Murphy previously held leadership roles at Horizon Therapeutics, including Group VP Commercial Operations and Business Development.
- THB335 IND-enabling toxicology studies nearing completion; pre-IND FDA interaction complete.
- Company on track to file U.S. IND and initiate Phase 1 SAD/14-day MAD study in first half of 2024.
- Cash and cash equivalents $273.9M as of Sept 30, 2023; strong financial position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1923840/000119312524001929/0001193125-24-001929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1923840/000119312524001929/d107873d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer